Denileukin diftitox transforms CTCL treatment by targeting malignant T cells, offering hope for patients with limited options and severe symptoms.
Myron Czuczman, MD
Advertisement
Articles by Myron Czuczman, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Sevabertinib in 1L HER2+ NSCLC
2
BI-1808/Pembrolizumab Shows Promising Activity in Recurrent Ovarian Cancer
3
NDA for Rusfertide Submitted to FDA for Polycythemia Vera
4
Adjuvant IO Exposure Complicates Treatment Selection for mRCC
5